Key facts
- This page summarizes Margaret Dalesandro's Form 4 filing for Ambrx Biopharma Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Sep 2023, 17:52.
Margaret Dalesandro - 01 Sep 2023 Form 4 Insider Report for Ambrx Biopharma Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Sep 2023, 17:52:23 UTC
- Prior SEC filing
- 29 Aug 2023
- Next SEC filing
- 06 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sonja Nelson, Attorney-in-Fact for Margaret Dalesandro
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Margaret Dalesandro filed Form 4 for Ambrx Biopharma Inc. on 06 Sep 2023.
Change
- Previous filing in this sequence was filed on 29 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMAM
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +125,000
- Change %
- Price
- $0.000000
- Shares after
- 125,000
- Date
- 01 Sep 2023
- Ownership
- Direct
- Footnotes
- F1, F2
AMAM
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +70,833
- Change %
- Price
- $0.000000
- Shares after
- 70,833
- Date
- 01 Sep 2023
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer.
Footnote F2
Represents the grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest in three successive equal annual installments beginning on September 1, 2024, subject to continuous service through such vesting date.
Footnote F3
Represents the grant of RSUs payable solely in Ordinary Shares of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the day immediately before the next annual general meeting, subject to continuous service through such vesting date.